VERV Projected Dividend Yield
Verve Therapeutics Inc ( NASDAQ : VERV )Verve Therapeutics, Inc. is a clinical-stage genetic medicines company. Co. is focused on developing a new approach to the care of cardiovascular disease (CVD), transforming treatment from chronic management to single-course gene editing medicines. Co.'s lead programs include VERVE-101, VERVE-102, and VERVE-201, which target genes that have been validated as targets for lowering low-density lipoprotein cholesterol (LDL-C), a root cause of atherosclerotic cardiovascular disease (ASCVD). VERVE-101 and VERVE-102 are designed to permanently turn off the PCSK9 gene in the liver and are being developed initially for heterozygous familial hypercholesterolemia (HeFH). 21 YEAR PERFORMANCE RESULTS |
VERV Dividend History Detail VERV Dividend News VERV Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |